Icon

TOPAMAX (nda020505)- (25MG,50MG,100MG,200MG,300MG,400MG)

TOPIRAMATE JANSSEN PHARMS
25MG,50MG,100MG,200MG,300MG,400MG
Yes No
2016-Apr-13 Expired
None None
None No
TOPAMAX  is indicated for: • Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older • Preventive treatment of migraine in patients 12 years of age and older
13 0 8
Total Other Developers 3
Drugs with Suitability No
25MG ** ** Up - 7
50MG ** ** Up - 7
100MG ** ** Up - 7
200MG ** ** Up - 7
300MG ** ** - - -
400MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 8
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** *** ***** ******* *********** **** *-*, *-**, *-** **** ********** ****, ******** *******, ******-*****, ****, *********** ******, ***** (***) ***
****** ***** *** ***** ******* *** *********** **********, *** ****** ****, *********, ********* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** ** *-*, ******* ********** ******, *******-******,, ***, ** ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ****** **. ***, *** & ***, ******* ***** ******** ******* ** * *, *******-*******, ***-******, ****. - *********, *********, ******* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ****** ******** ****** ******* ******* *** *********** ****-*, ****** **. ***, ***, ***, *** ** *** ******** *******, ********* ******, **********, ********* ******, ***** (***) ***
****** ******* ****** ******* ***************, *** *********** * **** ***., *********, *** **** (**) *****, ****** ****** (***) ***
****** ******* ****** ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ******* ****** ******* ***************, *** *********** *** * ******** *****, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ******* **** *** ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ******* **** *** ******* ************ ******* *********** **** **. ** ** **, ******* ********** ******, *******, ******, *** ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** ****** ****** *** ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.